• Users Online: 268
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO THE EDITOR
Year : 2020  |  Volume : 8  |  Issue : 1  |  Page : 33-34

Anticalcitonin gene-related peptide monoclonal antibodies: An overview


Department of Neurology; Department of Medicine, Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil

Date of Submission19-Oct-2019
Date of Decision16-Nov-2019
Date of Acceptance24-Nov-2019
Date of Web Publication14-Jan-2020

Correspondence Address:
Jamir Pitton Rissardo
Rua Roraima 1000, Santa Maria, Rio Grande do Sul
Brazil
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/AJIM.AJIM_70_19

Rights and Permissions

How to cite this article:
Rissardo JP, Fornari Caprara AL. Anticalcitonin gene-related peptide monoclonal antibodies: An overview. APIK J Int Med 2020;8:33-4

How to cite this URL:
Rissardo JP, Fornari Caprara AL. Anticalcitonin gene-related peptide monoclonal antibodies: An overview. APIK J Int Med [serial online] 2020 [cited 2020 Jul 6];8:33-4. Available from: http://www.ajim.in/text.asp?2020/8/1/33/275984



Sir,

We read the article “Chronic Migraine: Erenumab, New Kid on the Block” on the esteemed “APIK Journal of Internal Medicine” with great interest. In the article, Goel reviewed the new drug erenumab that has been approved by the Food and Drug Administration (FDA) in the last year.[1]

Headaches substantially affect the quality of life, causing disability in patients. In this context, migraine is a primary headache disorder that can occur episodic or chronic. The development of new therapies to this disease was limited throughout the years; first, the oral medication; after that occurred the approval of botulinum toxin. In 2018, the anticalcitonin gene-related peptide (anti-CGRP) monoclonal antibodies were available.[2]

Here, we would like to do a table with the other anti-CGRP antibodies already approved by the FDA that together with the study of Goel could lead to a better comprehension of the management of this group of medications [Table 1].[2],[3],[4],[5],[6] It is worthy of mentioning that due to the price, the majority of the insurance companies in the United States will request a previous trial of 2–4 drugs before releasing the anti-CGRP. In addition, most of the studies only started these medications after the failure of at least four drugs, so these molecules are not still the first drug of choice, and they are indicated only in refractory cases.[3],[6]
Table 1: Anticalcitonin gene-related peptide monoclonal antibodies

Click here to view


Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Go Goel D. Chronic migraine: Erenumab, new kid on the block. APIK J Int Med 2019;7:142-4.  Back to cited text no. 1
  [Full text]  
2.
Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD. CGRP monoclonal antibodies for migraine: Rationale and progress. BioDrugs 2017;31:487-501.  Back to cited text no. 2
    
3.
Scuteri D, Adornetto A, Rombolà L, Naturale MD, Morrone LA, Bagetta G, et al. New trends in migraine pharmacology: Targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies. Front Pharmacol 2019;10:363.  Back to cited text no. 3
    
4.
Saper J, Lipton R, Kudrow D, Hirman J, Dodick D, Silberstein S, et al. Primary Results of PROMISE-1 (Prevention of Migraine Via Intravenous Eptinezumab Safety and Efficacy–1) Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episodic Migraines (S20. 001). AAN Enterprises; 2018.  Back to cited text no. 4
    
5.
Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017;377:2123-32.  Back to cited text no. 5
    
6.
Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, et al. Blocking CGRP in migraine patients – A review of pros and cons. J Headache Pain 2017;18:96.  Back to cited text no. 6
    



 
 
    Tables

  [Table 1]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References
Article Tables

 Article Access Statistics
    Viewed125    
    Printed1    
    Emailed0    
    PDF Downloaded38    
    Comments [Add]    

Recommend this journal